Highlights EPIRUS Biopharmaceuticals, Inc.

Equities

EPRSQ

US29428P1075

Delayed OTC Markets Other stock markets 14:34:32 2024-02-06 EST			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2018	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
2018	Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	18-01-30	CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18-01-17	CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	16-06-29	CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	16-06-13	CI
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-15	CI
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	16-02-09	CI
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	15-11-16	CI
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-16	CI
Taro Pharmaceuticals Inc. acquired Zalicus Pharmaceuticals Ltd. from EPIRUS Biopharmaceuticals, Inc. for CAD 60.3 million.	15-10-06	CI
EPIRUS Biopharmaceuticals, Inc. acquired Bioceros B.V.	15-09-08	CI
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-07	CI
Epirus Biopharmaceuticals Signs Multi-Product, Multi-Region Profit-Sharing Collaboration with Polpharma Group	15-07-14	CI
EPIRUS Seeks Acquisitions	15-07-01	CI
Epirus Biopharmaceuticals Signs Up mAbxience as New Development, Distribution Partner for BOW015	15-05-14	CI
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-05-12	CI
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014	15-03-23	CI
EPIRUS Biopharmaceuticals, Inc. Launches its First Product Infimab in India	14-12-02	CI
Epirus Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-09	CI
EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China	14-10-31	CI
Epirus Biopharmaceuticals Receives Final Marketing and Manufacturing Approvals for its Remicade niosimilar, BOW015 from Drug Controller General of India	14-09-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights EPIRUS Biopharmaceuticals, Inc.

Equities

EPRSQ

US29428P1075

Highlights

Filters